Susan Gilmour, PhD, professor at Lankenau Institute for Medical Research (LIMR), has been elected by her scientific peers to chair the distinguished Gordon Research Conference on Polyamines to be held in New Hampshire in 2017. This leadership role is a significant honor, as the bi-annual conference will provide an opportunity to showcase key polyamines discoveries of acclaimed scientists from around the world. Polyamines, which are small organic compounds found in all cells, are closely linked to cell growth, survival and proliferation.
Historically the conference has focused on the study of the polyamine metabolic pathway as a target for chemotherapeutic intervention in cancer treatment. Speakers have discussed the role of polyamines in a wide range of pathological states including cancer, neurodegenerative diseases, and infection with parasites or bacteria.
“The conference has an 86-year history of sequestering world-class scientists in often remote locations to focus on the scientific exchange of ideas and to build new collaborations,” said Dr. Gilmour. “The 2017 meeting is critical, as there have been recent discoveries in the polyamine field that can lead to improved human health.”
The international conference will be held in Waterville Valley, NH, in June 2017. Approximately 150 to 200 acclaimed scientists from around the world are expected to be invited to attend.
The Gordon Research Conferences promote discussions and the free exchange of ideas at the research frontiers of the biological, chemical and physical sciences. Scientists with common professional interests come together for a week of intense discussion and examination of the most advanced aspects of their fields.
Dr. Gilmour’s research focuses on mechanisms by which tumor modifiers, such as polyamines, support and accelerate the development of cancer to a malignant, metastatic state. Her overriding goal is to translate her findings about the role of polyamines in cancer to polyamine-targeted therapies that can contribute to increased survival in cancer patients.